The role of chemotherapy in the hospice patient

Abstract

Get full access to this article

View all access options for this article.

References

Bulkin W , Lukashok H : Rx for dying: The case for Hospice. N Eng J Med, l988;318:376-378

Fed. Register, Vol 48:243, section 418.22 and 418.26, December 16, 1983

Mackillop W , O'Sullivan B , Ward G : Nonsmall cell cancer: How oncologists want to be treated. Int J Red Onc Bio Phys. 1987;13:929-934

Wolff SN , Herzig RH , Fay JW , et al: High dose Thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: Results of phase I and II stydies of the North American bone marrow transplantation group. J Clin Onc 1989;7:245-249

Love RR , Leventhal H , Easterling DV , Nerenz DR : Side Effects and emotional distress during cancer chemotherapy. Cancer 1989;63:604-612

Kushner R : Is aggressive adjuvant chemotherapy the Haisted radical of the “80's”? Ca- A Cane J for Clinc l984;34;345-351

Canellos GP , De Vita VT , Gold GL . et a1 Combination chemotherapy for advanced breast cancer: Response and effect on survival. Ann Intern Med 1976;84;389-392

Patel J , Takuma N , Vezeridis M , et al: Dose more intense palliative treatment improve over all survival in metastatic breast cancer patients? Cancer l986;57:567-570

Ross M , Buzdar A , Smith T , et al: Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 1985;55:341-346

10.

Rapp E , Pater J , Willana , et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer. A report of a Canadian multicenter randomized trial. J Clin Onc 1988;6:633-641

11.

Einhom L , Loehrer P , Williams S , et al: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine, cisplatin, mitomycin C in advanced nonsmall-cell lung cancer. J Clin Onc 1986;4:1037-1043

12.

Buccheri GF , Ferrigno D , Curcio A , et al: Continuation of chemotherapy versus supportive care alone in patients with inoperable nonsmall cell lung cancer and stable disease after two or three cycles of MACC: Results of a randomized prospective trial. Cancer 1989;63:428-432

13.

Armitage J , Cheseon B : Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Onc. 1988;6:1335-1347

14.

Vose JM , Armitage JO , Weisenburger DD , et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Onc l988;6:1838-1844

15.

Greenberg ER , Dam B , Freeman D , Yates D , Korson R : Referral of lung cancer patients to university hospital cancer centers: A population-based study in two rural states. Cancer 1988;62:1647-1652

16.

Daley J , Jencks S , Draper D , et al: Prediciting hospital-associated mortality for medicare patients: A method for patients with stroke, pneumonia, a cute myocardial infarction, and congestive heart failure. JAMA 1988; 260:3125-3163

17.

Tezzoni Li , Moskowitz MA : A clinical assessment of Medisgroups. JAMA 1988; 260:3159-3163

18.

Evans C , McCarthy M : Prognostic uncertainty in terminal care: Can the Karnofsky Index help? Lancet l985;1:1204-1206

19.

Forster LB Lynn J : Predicting life span for applicants to impatient hospices. Arch Int Med. 1988; 148:205-2543

20.

Pearlman RA : Inaccurate predictions of life expectancy: Dilemmas and opportunities (ed) Arch Int Med 1988;148:2537-2538

21.

Yates JW , Chalmer B , McKegney FP : Evaluation of patients with advance cancer using the Karnofsky performance status. Cancer 1980;45:220-224

22.

Reuben D , Nor V. Hiris J : Clinical symptoms and length of survival in patients with terminal cancer. Arch Int Med 1988;148:1586-1591

23.

Huben RP , Murphy GP : Prostate cancer an update. CA-A Canc J for Clinic. 1986;36:274-292

24.

Tong D , Gilhick L , Hendrickson F : The palliation of symptomatic osseus metastases, final results of RTOG study. Cancer 1982;50:893-899

25.

Kemeny N , Niedzwiecki D , Shurgot B. Oderman P : Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 1989;63:742-747

26.

Falkson G , Gelman R , Tormey D et al: The Eastern cooperative oncology group experience with cytoxan, adriamycin, and 5 fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 1985;56:219-224

27.

Tormey D , Gelman R , Band P , et al: Comparison of induction chemotherapy for metastatic breast cancer. Cancer l982;50:1235-1244

28.

Choi N , Carey R , Kaufman S et al: Small cell carcinoma of the lung: A progress report of 15 years experience. Cancer 1987;59:6-14

29.

Feld R , Evans W , Coy P , et al: Canadian multicenter randomized trial comparing sequential and alternating chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Onc. 1987;5:1401-1409

30.

Havenniann K , Wolf M , Holler R , et al: Alternating versus sequential chemotherapy in small cell lung cancer: A randomized German multicenter trial. Cancer 1987;59:l072-1082

31.

Hirsch F , Hansen H , Hansen M , et al: The superiority of combination chemotherapy ineluding etoposide, based on in vivocell cycle analysis in in the treatment of extensive small cell lung cancer: A randomized trial of 288 consecutive patients. J Clin Onc 1987;5:585-591

32.

Vuncent R , Wilson H , Lane W , et al: Progress in the chemotherapy of small cell carcinoma of the lung. Cancer 1981;47:229-235

33.

Osterland K , Hansen H , Hansen M , et al: Long-term disease-free survival in small-cell carcinoma of the lung, a study of clinical determinants. I Clin Onc 1986;4:l307-13l3

34.

Papac R , Son Y , Bien R , et al: Improved local control of thoracic disease in small cell lung cancer with higher dose thoraci irradiation and cyclic chemotherapy. Int J Rad Onc Bio Phy 1987;13:993-998

35.

Devita V. Helhnan S , Rosenberg S (ed): Cancer, Principles and Practice of Oncology, 2nd Ed; pp 257-285. Philidelphia, J.B. Lippincott Co., 1985

36.

Kaplan LD , Abranis DI , Feigal E , et al: AIDS associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-724

37.

Gills PS , Levine AM , Krailo M et al: Aids related malignant lymphoma: results of prospective treatment trials. J Clin Onc 1987;5:1322-1328

38.

Klatersky J , Sculier JP , Ravez P , et al: A randomized study comparing a high and standard dose of cisplalin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Onc 1986;4:1780-1786

39.

Griffin TW , Hunter RA , Cederbaum Al , et al: Treatment of advanced ovarian cancer with sequential combination chemotherapy. Cancer 1987;60:2150-2155

40.

Piver S. Lele S. Marchetti D , et al: The impact of aggressive debulking surgery and cisplatun-based chemotherapy on progression free survival in stage III and IV ovarian cancer. J Clin Onc 1988;6:983-989

41.

Kardinal C , Perry M , Korzun A , et al: Responses to chemotherapy or chemo-hormonal therapy in advanced breast cancer patients previously treated with adjuvant chemotherapy. Cancer 1988;61:415-419

42.

Maurer L , Tulloh M , Weiss R , et al: A randomized combined modality trial in small cell carcinoma of the lung. Cancer 1980;45:30-39

43.

Millstein D , Robinson E : Four-drug combination chemotherapy in advanced lung cancer: Methotrexate, doxorubicin, cyclophosphamide, and CCNU. Cancer 1981;48:2358-2363

44.

Shepard K , Golomb H , Bitran J , et al: CAMP chemotherapy for metastatic no-oat cell bronchogenic carcinoma. Cancer 1985;56:2385-2390

45.

Rodriquez-Kraul R , Hortobagyi G , Buzdar A , Blumenschein G : Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer 1981;48:227-232

46.

Jones R , Holland J , Bhardwaj S , et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Onc 1987;5:172-177

47.

Romond E , Metcalfe M , MacDonald J : Palliative chemotherapy and hormonal therapy. Sem One. 1985;12:384-389

48.

Sorensen J , Hansen H , Dombernowsky P , et al. Chemotherapy for adenocasrcinoma of the lung (WHO III): A randomized study of viadesine versus lomustine, cyclophoasphamide, and methotrexate versus all four drugs. J Clin Onc 1987;5:1169-1177

49.

Popert K , Anderson J : Assessing the effect of toxicity on prognosis: Methods of analysis and interpretation. J Clin Onc 1988;6:868-870

50.

Bonadonna G , Valgussa P : Dose-response effect of adjuvant chemotherapy in breast cancer. N. Eng J Med 1981;304:10-15

51.

Hryniuk W , Levine M : Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Onc. 1986;4:1162-1170

52.

Ahmann D , Sehaid D , Bisel H , Hahn R , et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Onc 1987;5:1928-1932

53.

Carbone P : High-dose chemotherapy for breast cancer (ed) J Clin Onc 1987;5:167-168

54.

Rosner D , Nemoto T , Lane W : A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer 1987;59:874-883

55.

Jones R , Holland J , Bhardwaj S , et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Onc 1987;5:172-177

56.

Tannoek I , Boyd N , Deboer G , et al: A randomized trial of low dose levels of cytoxan, methotrexate, a 5-fluorouracil chemotherapy for patients with metastatic breast cancinoma. Cancer 1988;6:1377-1387

57.

Hum S , Pazdur R , Singhakowinta A , et al: Low-dose continuous infusion 5-fluorouracil: Evaluation in advanced breast carcinoma. Cancer 1989;63:419-422

58.

Valagussa P. Taneini G , Bonadonna G : Salvage treatment of patients suffering relapse after adjuv ant CMF chemotherapy. Cancer 1986;58:1411-1417

59.

Rapp E , Peter J, Willana , et al: Chemotherapy can prolong survival in patients in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Onc. 1988;6:633-641

60.

Thatcher N , Cerny T , Stout R , et al: Ifos-famide, etoposide, and thoraeie irradiation in 163 patients with unreseetable small cell lung carcinoma. Cancer 1987;60:2382-2387

61.

York RM , Foltz A : Bleomycin, vineristine, lomustine, and DTIC chemotherapy for metastatie melanoma. Cancer 1988;61:2183-2183

62.

Kies M , Mira J , Crowley J , et al: Multirnodal therapy for limited small-cell lung cancer. Arndomized study of induction combination chemotherapy with or without thoraci radiation in complete responders; and with wide-field versus reduced files radiation in partial responders: A Southwest Oncology Group Study. J Clin Onc 1987;5:592-600

63.

Aaronson NK : Quality of life: What is it? How should it be measured? Oncology 1988;2:69-7651

64.

Fettung JH : Evaluating quality and quantity of life in breast cancer adjuvanttrials (ed). J Clin Onc 1988;6:1795-1797

65.

Schipper H , Levitt M : Measuring quality of life, risks and benefits. Cane Treat Rpts 1985;69:1115-1123

66.

Spitzer W , Dobson A , Hall J , et al: Measuring the quality of life of cancer patients. J Chron Dis 1981;34:585-597

67.

Bartelink H , Van Dam F , Van Dongen J : Psychological effects of breast conserving therapy in comparison with radical mastectomy. Int J Rad Onc Bio Phys 1985;11:381-385

68.

Evans R , Mannine D , Garrison L , et al: Quality of life of patients with end-stage renal disease. N Eng J Med 1985;312:553-559

69.

Vera M : Quality of life following pelvic exenteration. Gyn One 1981;12:355-366

70.

Lanham R , DiGiannantonio A : Quality of life of Cancer Patients. Oncology 1988;(45)1-7

71.

McNeil B , Weichselbaum R , Pauker S : Speech and survival tradeoffs between quality and quantity of life in laryngeal cancer. N Eng J Med 1981;305:982-987

72.

Priestman T , Baum M : Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976;1:899-900

73.

Gelber R , Goldhirsch A : A new endpoint for the assesment of adjuvant therapy in postmenopausal women with operable breast cancer, J Clin Onc 1986;4:1772-1779

74.

Goodwin PJ , Feld R , Evans WK , Pater J : Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. Journal of Clin Onc 1988;6:1537-1547

75.

Levine MN , Guyatt GH , Gent M , et al: Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Onc 1988;6:1789-1810

76.

Goldhirsch A , Gelber RD , Simes RJ , et al: Costs and benefits of adjuvanttherapy in breast cancer: A quality-adjusted survival analysis. J Clin Onc. 1989;7:36-44